Intellia Therapeutics, Inc.
Clinical-stage gene-editing company developing systemic in vivo CRISPR/Cas9 therapies, led by lonvoguran ziclumeran (lonvo-z) in hereditary angioedema and nexiguran ziclumeran (nex-z) in ATTR.
Rare Disease / Genetic Medicine · In vivo CRISPR/Cas9 gene editing · Late-stage / BLA submission + Phase 3